These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 23699655)

  • 1. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
    Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
    Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
    Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
    Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
    Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
    Rajeshkumar NV; De Oliveira E; Ottenhof N; Watters J; Brooks D; Demuth T; Shumway SD; Mizuarai S; Hirai H; Maitra A; Hidalgo M
    Clin Cancer Res; 2011 May; 17(9):2799-806. PubMed ID: 21389100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
    Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
    Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.
    Ghelli Luserna di Rorà A; Cerchione C; Martinelli G; Simonetti G
    J Hematol Oncol; 2020 Sep; 13(1):126. PubMed ID: 32958072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
    Bridges KA; Hirai H; Buser CA; Brooks C; Liu H; Buchholz TA; Molkentine JM; Mason KA; Meyn RE
    Clin Cancer Res; 2011 Sep; 17(17):5638-48. PubMed ID: 21799033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
    Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
    Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 13. Wee1 kinase as a target for cancer therapy.
    Do K; Doroshow JH; Kummar S
    Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
    Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
    Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Wee1-like protein kinase to treat cancer.
    Stathis A; Oza A
    Drug News Perspect; 2010 Sep; 23(7):425-9. PubMed ID: 20862394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
    Hirai H; Arai T; Okada M; Nishibata T; Kobayashi M; Sakai N; Imagaki K; Ohtani J; Sakai T; Yoshizumi T; Mizuarai S; Iwasawa Y; Kotani H
    Cancer Biol Ther; 2010 Apr; 9(7):514-22. PubMed ID: 20107315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
    Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
    Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
    Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
    Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
    Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
    Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.